

Global Pseudorabies Virus Vaccine Market Growth 2026-2032

<https://marketpublishers.com/r/G52BB070F231EN.html>

Date: July 2026

Pages: 131

Price: US\$ 3,660.00 (Single User License)

ID: G52BB070F231EN

Abstracts

The global Pseudorabies Virus Vaccine market size is predicted to grow from US\$ 165 million in 2025 to US\$ 253 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.

Pseudorabies Virus Vaccine is a veterinary biological product used to protect pigs against pseudorabies virus infection, mainly covering piglets, fattening pigs, replacement gilts, sows and boars. It helps reduce clinical disease, mortality, reproductive losses and virus shedding in swine herds. The product scope mainly includes live attenuated vaccines, inactivated vaccines, gene-deleted marker vaccines and combination vaccines containing pseudorabies virus antigens, with freeze-dried live vaccines and oil-emulsion inactivated vaccines as the main product forms. The most common and highest-volume strain platforms are Bartha-K61, HB98 and C strain. Upstream inputs mainly include production strains, cell substrates, culture media, adjuvants, stabilizers, freeze-drying protectants, inactivating agents, packaging materials and cold-chain packaging materials. Downstream customers mainly include large-scale swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors and animal disease control bodies. On an ex-factory finished-vaccine basis, global designed capacity in 2025 is estimated at about 2.28 billion doses, actual sales volume at about 1.64 billion doses, and the average ex-factory ASP at around USD 0.10 per dose, with an industry gross margin of about 46%?61%. Differentiated products such as marker vaccines, variant-strain inactivated vaccines and combination vaccines generally carry higher prices and margins than conventional live vaccines.

The current market for Pseudorabies Virus Vaccine is already a mature commercial segment within swine vaccines, with stable baseline immunization demand but clear regional differences. China and selected intensive swine-producing regions in Asia

remain the most active demand centers, as large-scale farms continue to focus on reproductive stability, piglet survival, fattening herd health and farm-level purification programs. In parts of Europe and North America, disease eradication and monitoring systems are more mature, so commercial vaccine demand is relatively stable and mainly supported by a limited number of multinational animal health companies. Overall, this is not a high-growth emerging market, but a stable market driven by routine vaccination, product upgrading and higher-quality disease-control needs. Looking ahead, competition will gradually shift from the supply of conventional vaccines to comprehensive prevention solutions that better fit the immunization programs of large-scale swine farms. Integrated producers are paying more attention to strain matching, duration of protection, batch-to-batch consistency, safety and compatibility with other swine vaccines. This will encourage manufacturers to keep upgrading live vaccines, inactivated vaccines, gene-deleted marker vaccines and combination vaccines. Companies with stable manufacturing processes, strong strain reserves, field validation capabilities and farm-level technical service teams will be better positioned to enter the supplier systems of large farming groups. Future product value will come more from purification support, variant-strain control and improved overall immunization efficiency than from low-price competition alone. The main growth drivers include the expansion of intensive pig farming, normalized disease prevention, the need to improve sow productivity and demand for regional herd purification. Once pseudorabies spreads within a farm, it can cause meaningful production losses in breeding sows, piglets and fattening pigs, so large-scale farms usually include it in their stable vaccination management systems. As producers raise their requirements for biosecurity, disease monitoring and production performance, the value of vaccine suppliers is no longer limited to the product itself. It also includes immunization program design, antibody monitoring support, purification-route advice and on-site technical services. Stricter regulation and higher quality requirements for veterinary biological products also favor suppliers with stronger technical capabilities and more complete quality systems. Key restraints include hog-cycle volatility, product homogenization, lower demand in some purified regions and the difficulty of proving clear product differentiation. When farm profitability is weak, small and medium-sized farms may reduce disease-prevention spending, affecting routine vaccine purchases. At the same time, many suppliers compete in mainstream strain platforms, creating pressure from channels and pricing. For new-generation marker vaccines, variant-strain inactivated vaccines and combination products, research, registration, field validation and scaled manufacturing all require long development cycles, so commercialization is not easy. The market is expected to become more concentrated around companies with broader product portfolios, stable manufacturing quality, strong access to integrated farming groups and solid technical service capabilities, while smaller suppliers without clear differentiation

may face increasing competitive pressure.

LP Information, Inc. (LPI) ' newest research report, the "Pseudorabies Virus Vaccine Industry Forecast" looks at past sales and reviews total world Pseudorabies Virus Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Pseudorabies Virus Vaccine sales for 2026 through 2032. With Pseudorabies Virus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Pseudorabies Virus Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Pseudorabies Virus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pseudorabies Virus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pseudorabies Virus Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pseudorabies Virus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pseudorabies Virus Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Pseudorabies Virus Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Live Attenuated Vaccine

Inactivated Vaccine

Others

Segmentation by Strain Platform:

Bartha-K61 Strain

HB98 Strain

C Strain

Other

Segmentation by Dose Pack Size:

Small Pack (Below 20 Doses per Vial)

Medium Pack (20-50 Doses per Vial)

Large Pack (Above 50 Doses per Vial)

Segmentation by Application:

Large-scale Swine Farming Groups

Breeding Farms

Animal Disease Control Institutions

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

MSD Animal Health

Boehringer Ingelheim

HIPRA

Ceva Santé Animale

Wuhan Keqian Biology

Pulike Biological Engineering

China Animal Husbandry Industry

Jinyu Bio-Technology

Guangdong Winsun Bio-Pharmaceutical

Huapai Biopharm

Jilin Zhengye Biological Products

Sinopharm Yangzhou VAC Biological Engineering

Sinovet Animal Health

Jofunhwa Group

Harbin Weike Biotechnology

Qilu Animal Health Products

Harbin Pharmaceutical Group Bio-vaccine

Qingdao Yebio Bioengineering

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pseudorabies Virus Vaccine market?

What factors are driving Pseudorabies Virus Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pseudorabies Virus Vaccine market opportunities vary by end market size?

How does Pseudorabies Virus Vaccine break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Pseudorabies Virus Vaccine Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Pseudorabies Virus Vaccine by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Pseudorabies Virus Vaccine by Country/Region, 2021, 2025 & 2032
- 2.2 Pseudorabies Virus Vaccine Segment by Type
 - 2.2.1 Live Attenuated Vaccine
 - 2.2.2 Inactivated Vaccine
 - 2.2.3 Others
 - 2.2.4 Pseudorabies Virus Vaccine Sales by Type
 - 2.2.4.1 Global Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
 - 2.2.4.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Type (2021-2026)
 - 2.2.4.3 Global Pseudorabies Virus Vaccine Sale Price by Type (2021-2026)
- 2.3 Pseudorabies Virus Vaccine Segment by Strain Platform
 - 2.3.1 Bartha-K61 Strain
 - 2.3.2 HB98 Strain
 - 2.3.3 C Strain
 - 2.3.4 Other
 - 2.3.5 Pseudorabies Virus Vaccine Sales by Strain Platform
 - 2.3.5.1 Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform (2021-2026)
 - 2.3.5.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Strain

Platform (2021-2026)

2.3.5.3 Global Pseudorabies Virus Vaccine Sale Price by Strain Platform (2021-2026)

2.4 Pseudorabies Virus Vaccine Segment by Dose Pack Size

2.4.1 Small Pack (Below 20 Doses per Vial)

2.4.2 Medium Pack (20-50 Doses per Vial)

2.4.3 Large Pack (Above 50 Doses per Vial)

2.4.4 Pseudorabies Virus Vaccine Sales by Dose Pack Size

2.4.4.1 Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size (2021-2026)

2.4.4.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)

2.4.4.3 Global Pseudorabies Virus Vaccine Sale Price by Dose Pack Size (2021-2026)

2.5 Pseudorabies Virus Vaccine Segment by Application

2.5.1 Large-scale Swine Farming Groups

2.5.2 Breeding Farms

2.5.3 Animal Disease Control Institutions

2.5.4 Others

2.5.5 Pseudorabies Virus Vaccine Sales by Application

2.5.5.1 Global Pseudorabies Virus Vaccine Sale Market Share by Application (2021-2026)

2.5.5.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Application (2021-2026)

2.5.5.3 Global Pseudorabies Virus Vaccine Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Pseudorabies Virus Vaccine Breakdown Data by Company

3.1.1 Global Pseudorabies Virus Vaccine Annual Sales by Company (2021-2026)

3.1.2 Global Pseudorabies Virus Vaccine Sales Market Share by Company (2021-2026)

3.2 Global Pseudorabies Virus Vaccine Annual Revenue by Company (2021-2026)

3.2.1 Global Pseudorabies Virus Vaccine Revenue by Company (2021-2026)

3.2.2 Global Pseudorabies Virus Vaccine Revenue Market Share by Company (2021-2026)

3.3 Global Pseudorabies Virus Vaccine Sale Price by Company

3.4 Key Manufacturers Pseudorabies Virus Vaccine Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Pseudorabies Virus Vaccine Product Location Distribution

- 3.4.2 Players Pseudorabies Virus Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PSEUDORABIES VIRUS VACCINE BY GEOGRAPHIC REGION

- 4.1 World Historic Pseudorabies Virus Vaccine Market Size by Geographic Region (2021-2026)
 - 4.1.1 Global Pseudorabies Virus Vaccine Annual Sales by Geographic Region (2021-2026)
 - 4.1.2 Global Pseudorabies Virus Vaccine Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic Pseudorabies Virus Vaccine Market Size by Country/Region (2021-2026)
 - 4.2.1 Global Pseudorabies Virus Vaccine Annual Sales by Country/Region (2021-2026)
 - 4.2.2 Global Pseudorabies Virus Vaccine Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Pseudorabies Virus Vaccine Sales Growth
- 4.4 APAC Pseudorabies Virus Vaccine Sales Growth
- 4.5 Europe Pseudorabies Virus Vaccine Sales Growth
- 4.6 Middle East & Africa Pseudorabies Virus Vaccine Sales Growth

5 AMERICAS

- 5.1 Americas Pseudorabies Virus Vaccine Sales by Country
 - 5.1.1 Americas Pseudorabies Virus Vaccine Sales by Country (2021-2026)
 - 5.1.2 Americas Pseudorabies Virus Vaccine Revenue by Country (2021-2026)
- 5.2 Americas Pseudorabies Virus Vaccine Sales by Type (2021-2026)
- 5.3 Americas Pseudorabies Virus Vaccine Sales by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

6.1 APAC Pseudorabies Virus Vaccine Sales by Region

6.1.1 APAC Pseudorabies Virus Vaccine Sales by Region (2021-2026)

6.1.2 APAC Pseudorabies Virus Vaccine Revenue by Region (2021-2026)

6.2 APAC Pseudorabies Virus Vaccine Sales by Type (2021-2026)

6.3 APAC Pseudorabies Virus Vaccine Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Pseudorabies Virus Vaccine by Country

7.1.1 Europe Pseudorabies Virus Vaccine Sales by Country (2021-2026)

7.1.2 Europe Pseudorabies Virus Vaccine Revenue by Country (2021-2026)

7.2 Europe Pseudorabies Virus Vaccine Sales by Type (2021-2026)

7.3 Europe Pseudorabies Virus Vaccine Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Pseudorabies Virus Vaccine by Country

8.1.1 Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2021-2026)

8.1.2 Middle East & Africa Pseudorabies Virus Vaccine Revenue by Country (2021-2026)

8.2 Middle East & Africa Pseudorabies Virus Vaccine Sales by Type (2021-2026)

8.3 Middle East & Africa Pseudorabies Virus Vaccine Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Pseudorabies Virus Vaccine

10.3 Manufacturing Process Analysis of Pseudorabies Virus Vaccine

10.4 Industry Chain Structure of Pseudorabies Virus Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Pseudorabies Virus Vaccine Distributors

11.3 Pseudorabies Virus Vaccine Customer

12 WORLD FORECAST REVIEW FOR PSEUDORABIES VIRUS VACCINE BY GEOGRAPHIC REGION

12.1 Global Pseudorabies Virus Vaccine Market Size Forecast by Region

12.1.1 Global Pseudorabies Virus Vaccine Forecast by Region (2027-2032)

12.1.2 Global Pseudorabies Virus Vaccine Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Pseudorabies Virus Vaccine Forecast by Type (2027-2032)

12.7 Global Pseudorabies Virus Vaccine Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 MSD Animal Health

13.1.1 MSD Animal Health Company Information

13.1.2 MSD Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications

13.1.3 MSD Animal Health Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 MSD Animal Health Main Business Overview

13.1.5 MSD Animal Health Latest Developments

13.2 Boehringer Ingelheim

13.2.1 Boehringer Ingelheim Company Information

13.2.2 Boehringer Ingelheim Pseudorabies Virus Vaccine Product Portfolios and Specifications

13.2.3 Boehringer Ingelheim Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Boehringer Ingelheim Main Business Overview

13.2.5 Boehringer Ingelheim Latest Developments

13.3 HIPRA

13.3.1 HIPRA Company Information

13.3.2 HIPRA Pseudorabies Virus Vaccine Product Portfolios and Specifications

13.3.3 HIPRA Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 HIPRA Main Business Overview

13.3.5 HIPRA Latest Developments

13.4 Ceva Sant? Animale

13.4.1 Ceva Sant? Animale Company Information

13.4.2 Ceva Sant? Animale Pseudorabies Virus Vaccine Product Portfolios and Specifications

13.4.3 Ceva Sant? Animale Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Ceva Sant? Animale Main Business Overview

13.4.5 Ceva Sant? Animale Latest Developments

13.5 Wuhan Keqian Biology

13.5.1 Wuhan Keqian Biology Company Information

13.5.2 Wuhan Keqian Biology Pseudorabies Virus Vaccine Product Portfolios and Specifications

13.5.3 Wuhan Keqian Biology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Wuhan Keqian Biology Main Business Overview

- 13.5.5 Wuhan Keqian Biology Latest Developments
- 13.6 Pulike Biological Engineering
 - 13.6.1 Pulike Biological Engineering Company Information
 - 13.6.2 Pulike Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.6.3 Pulike Biological Engineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Pulike Biological Engineering Main Business Overview
 - 13.6.5 Pulike Biological Engineering Latest Developments
- 13.7 China Animal Husbandry Industry
 - 13.7.1 China Animal Husbandry Industry Company Information
 - 13.7.2 China Animal Husbandry Industry Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.7.3 China Animal Husbandry Industry Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 China Animal Husbandry Industry Main Business Overview
 - 13.7.5 China Animal Husbandry Industry Latest Developments
- 13.8 Jinyu Bio-Technology
 - 13.8.1 Jinyu Bio-Technology Company Information
 - 13.8.2 Jinyu Bio-Technology Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.8.3 Jinyu Bio-Technology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 Jinyu Bio-Technology Main Business Overview
 - 13.8.5 Jinyu Bio-Technology Latest Developments
- 13.9 Guangdong Winsun Bio-Pharmaceutical
 - 13.9.1 Guangdong Winsun Bio-Pharmaceutical Company Information
 - 13.9.2 Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.9.3 Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 Guangdong Winsun Bio-Pharmaceutical Main Business Overview
 - 13.9.5 Guangdong Winsun Bio-Pharmaceutical Latest Developments
- 13.10 Huapai Biopharm
 - 13.10.1 Huapai Biopharm Company Information
 - 13.10.2 Huapai Biopharm Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.10.3 Huapai Biopharm Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.10.4 Huapai Biopharm Main Business Overview
- 13.10.5 Huapai Biopharm Latest Developments
- 13.11 Jilin Zhengye Biological Products
 - 13.11.1 Jilin Zhengye Biological Products Company Information
 - 13.11.2 Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.11.3 Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.11.4 Jilin Zhengye Biological Products Main Business Overview
 - 13.11.5 Jilin Zhengye Biological Products Latest Developments
- 13.12 Sinopharm Yangzhou VAC Biological Engineering
 - 13.12.1 Sinopharm Yangzhou VAC Biological Engineering Company Information
 - 13.12.2 Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.12.3 Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.12.4 Sinopharm Yangzhou VAC Biological Engineering Main Business Overview
 - 13.12.5 Sinopharm Yangzhou VAC Biological Engineering Latest Developments
- 13.13 Sinovet Animal Health
 - 13.13.1 Sinovet Animal Health Company Information
 - 13.13.2 Sinovet Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.13.3 Sinovet Animal Health Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.13.4 Sinovet Animal Health Main Business Overview
 - 13.13.5 Sinovet Animal Health Latest Developments
- 13.14 Jofunhwa Group
 - 13.14.1 Jofunhwa Group Company Information
 - 13.14.2 Jofunhwa Group Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.14.3 Jofunhwa Group Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.14.4 Jofunhwa Group Main Business Overview
 - 13.14.5 Jofunhwa Group Latest Developments
- 13.15 Harbin Weike Biotechnology
 - 13.15.1 Harbin Weike Biotechnology Company Information
 - 13.15.2 Harbin Weike Biotechnology Pseudorabies Virus Vaccine Product Portfolios and Specifications
 - 13.15.3 Harbin Weike Biotechnology Pseudorabies Virus Vaccine Sales, Revenue,

Price and Gross Margin (2021-2026)

13.15.4 Harbin Weike Biotechnology Main Business Overview

13.15.5 Harbin Weike Biotechnology Latest Developments

13.16 Qilu Animal Health Products

13.16.1 Qilu Animal Health Products Company Information

13.16.2 Qilu Animal Health Products Pseudorabies Virus Vaccine Product Portfolios and Specifications

13.16.3 Qilu Animal Health Products Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 Qilu Animal Health Products Main Business Overview

13.16.5 Qilu Animal Health Products Latest Developments

13.17 Harbin Pharmaceutical Group Bio-vaccine

13.17.1 Harbin Pharmaceutical Group Bio-vaccine Company Information

13.17.2 Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Product Portfolios and Specifications

13.17.3 Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Harbin Pharmaceutical Group Bio-vaccine Main Business Overview

13.17.5 Harbin Pharmaceutical Group Bio-vaccine Latest Developments

13.18 Qingdao Yebio Bioengineering

13.18.1 Qingdao Yebio Bioengineering Company Information

13.18.2 Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Product Portfolios and Specifications

13.18.3 Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Qingdao Yebio Bioengineering Main Business Overview

13.18.5 Qingdao Yebio Bioengineering Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Pseudorabies Virus Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Pseudorabies Virus Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Live Attenuated Vaccine

Table 4. Major Players of Inactivated Vaccine

Table 5. Major Players of Others

Table 6. Global Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)

Table 7. Global Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)

Table 8. Global Pseudorabies Virus Vaccine Revenue by Type (2021-2026) & (\$ million)

Table 9. Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2021-2026)

Table 10. Global Pseudorabies Virus Vaccine Sale Price by Type (2021-2026) & (US\$/Dose)

Table 11. Major Players of Bartha-K61 Strain

Table 12. Major Players of HB98 Strain

Table 13. Major Players of C Strain

Table 14. Major Players of Other

Table 15. Global Pseudorabies Virus Vaccine Sales by Strain Platform (2021-2026) & (K Dose)

Table 16. Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform (2021-2026)

Table 17. Global Pseudorabies Virus Vaccine Revenue by Strain Platform (2021-2026) & (\$ million)

Table 18. Global Pseudorabies Virus Vaccine Revenue Market Share by Strain Platform (2021-2026)

Table 19. Global Pseudorabies Virus Vaccine Sale Price by Strain Platform (2021-2026) & (US\$/Dose)

Table 20. Major Players of Small Pack (Below 20 Doses per Vial)

Table 21. Major Players of Medium Pack (20-50 Doses per Vial)

Table 22. Major Players of Large Pack (Above 50 Doses per Vial)

Table 23. Global Pseudorabies Virus Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)

Table 24. Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size (2021-2026)

Table 25. Global Pseudorabies Virus Vaccine Revenue by Dose Pack Size (2021-2026) & (\$ million)

Table 26. Global Pseudorabies Virus Vaccine Revenue Market Share by Dose Pack Size (2021-2026)

Table 27. Global Pseudorabies Virus Vaccine Sale Price by Dose Pack Size (2021-2026) & (US\$/Dose)

Table 28. Global Pseudorabies Virus Vaccine Sale by Application (2021-2026) & (K Dose)

Table 29. Global Pseudorabies Virus Vaccine Sale Market Share by Application (2021-2026)

Table 30. Global Pseudorabies Virus Vaccine Revenue by Application (2021-2026) & (\$ million)

Table 31. Global Pseudorabies Virus Vaccine Revenue Market Share by Application (2021-2026)

Table 32. Global Pseudorabies Virus Vaccine Sale Price by Application (2021-2026) & (US\$/Dose)

Table 33. Global Pseudorabies Virus Vaccine Sales by Company (2021-2026) & (K Dose)

Table 34. Global Pseudorabies Virus Vaccine Sales Market Share by Company (2021-2026)

Table 35. Global Pseudorabies Virus Vaccine Revenue by Company (2021-2026) & (\$ millions)

Table 36. Global Pseudorabies Virus Vaccine Revenue Market Share by Company (2021-2026)

Table 37. Global Pseudorabies Virus Vaccine Sale Price by Company (2021-2026) & (US\$/Dose)

Table 38. Key Manufacturers Pseudorabies Virus Vaccine Producing Area Distribution and Sales Area

Table 39. Players Pseudorabies Virus Vaccine Products Offered

Table 40. Pseudorabies Virus Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 41. New Products and Potential Entrants

Table 42. Market M&A Activity & Strategy

Table 43. Global Pseudorabies Virus Vaccine Sales by Geographic Region (2021-2026) & (K Dose)

Table 44. Global Pseudorabies Virus Vaccine Sales Market Share Geographic Region (2021-2026)

Table 45. Global Pseudorabies Virus Vaccine Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 46. Global Pseudorabies Virus Vaccine Revenue Market Share by Geographic Region (2021-2026)

Table 47. Global Pseudorabies Virus Vaccine Sales by Country/Region (2021-2026) & (K Dose)

Table 48. Global Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2021-2026)

Table 49. Global Pseudorabies Virus Vaccine Revenue by Country/Region (2021-2026) & (\$ millions)

Table 50. Global Pseudorabies Virus Vaccine Revenue Market Share by Country/Region (2021-2026)

Table 51. Americas Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)

Table 52. Americas Pseudorabies Virus Vaccine Sales Market Share by Country (2021-2026)

Table 53. Americas Pseudorabies Virus Vaccine Revenue by Country (2021-2026) & (\$ millions)

Table 54. Americas Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)

Table 55. Americas Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)

Table 56. APAC Pseudorabies Virus Vaccine Sales by Region (2021-2026) & (K Dose)

Table 57. APAC Pseudorabies Virus Vaccine Sales Market Share by Region (2021-2026)

Table 58. APAC Pseudorabies Virus Vaccine Revenue by Region (2021-2026) & (\$ millions)

Table 59. APAC Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)

Table 60. APAC Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)

Table 61. Europe Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)

Table 62. Europe Pseudorabies Virus Vaccine Revenue by Country (2021-2026) & (\$ millions)

Table 63. Europe Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)

Table 64. Europe Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)

Table 65. Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)

Table 66. Middle East & Africa Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)

Table 67. Middle East & Africa Pseudorabies Virus Vaccine Sales by Type (2021-2026)

& (K Dose)

Table 68. Middle East & Africa Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)

Table 69. Key Market Drivers & Growth Opportunities of Pseudorabies Virus Vaccine

Table 70. Key Market Challenges & Risks of Pseudorabies Virus Vaccine

Table 71. Key Industry Trends of Pseudorabies Virus Vaccine

Table 72. Pseudorabies Virus Vaccine Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Pseudorabies Virus Vaccine Distributors List

Table 75. Pseudorabies Virus Vaccine Customer List

Table 76. Global Pseudorabies Virus Vaccine Sales Forecast by Region (2027-2032) & (K Dose)

Table 77. Global Pseudorabies Virus Vaccine Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 78. Americas Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 79. Americas Pseudorabies Virus Vaccine Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 80. APAC Pseudorabies Virus Vaccine Sales Forecast by Region (2027-2032) & (K Dose)

Table 81. APAC Pseudorabies Virus Vaccine Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 82. Europe Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 83. Europe Pseudorabies Virus Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 84. Middle East & Africa Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 85. Middle East & Africa Pseudorabies Virus Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 86. Global Pseudorabies Virus Vaccine Sales Forecast by Type (2027-2032) & (K Dose)

Table 87. Global Pseudorabies Virus Vaccine Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 88. Global Pseudorabies Virus Vaccine Sales Forecast by Application (2027-2032) & (K Dose)

Table 89. Global Pseudorabies Virus Vaccine Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 90. MSD Animal Health Basic Information, Pseudorabies Virus Vaccine

Manufacturing Base, Sales Area and Its Competitors

Table 91. MSD Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 92. MSD Animal Health Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 93. MSD Animal Health Main Business

Table 94. MSD Animal Health Latest Developments

Table 95. Boehringer Ingelheim Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 96. Boehringer Ingelheim Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 97. Boehringer Ingelheim Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 98. Boehringer Ingelheim Main Business

Table 99. Boehringer Ingelheim Latest Developments

Table 100. HIPRA Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 101. HIPRA Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 102. HIPRA Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 103. HIPRA Main Business

Table 104. HIPRA Latest Developments

Table 105. Ceva Sant? Animale Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 106. Ceva Sant? Animale Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 107. Ceva Sant? Animale Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 108. Ceva Sant? Animale Main Business

Table 109. Ceva Sant? Animale Latest Developments

Table 110. Wuhan Keqian Biology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 111. Wuhan Keqian Biology Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 112. Wuhan Keqian Biology Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 113. Wuhan Keqian Biology Main Business

Table 114. Wuhan Keqian Biology Latest Developments

Table 115. Pulike Biological Engineering Basic Information, Pseudorabies Virus Vaccine

Manufacturing Base, Sales Area and Its Competitors

Table 116. Pulike Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 117. Pulike Biological Engineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 118. Pulike Biological Engineering Main Business

Table 119. Pulike Biological Engineering Latest Developments

Table 120. China Animal Husbandry Industry Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 121. China Animal Husbandry Industry Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 122. China Animal Husbandry Industry Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 123. China Animal Husbandry Industry Main Business

Table 124. China Animal Husbandry Industry Latest Developments

Table 125. Jinyu Bio-Technology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 126. Jinyu Bio-Technology Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 127. Jinyu Bio-Technology Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 128. Jinyu Bio-Technology Main Business

Table 129. Jinyu Bio-Technology Latest Developments

Table 130. Guangdong Winsun Bio-Pharmaceutical Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 131. Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 132. Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 133. Guangdong Winsun Bio-Pharmaceutical Main Business

Table 134. Guangdong Winsun Bio-Pharmaceutical Latest Developments

Table 135. Huapai Biopharm Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 136. Huapai Biopharm Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 137. Huapai Biopharm Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 138. Huapai Biopharm Main Business

Table 139. Huapai Biopharm Latest Developments

Table 140. Jilin Zhengye Biological Products Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 141. Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 142. Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 143. Jilin Zhengye Biological Products Main Business

Table 144. Jilin Zhengye Biological Products Latest Developments

Table 145. Sinopharm Yangzhou VAC Biological Engineering Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 146. Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 147. Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 148. Sinopharm Yangzhou VAC Biological Engineering Main Business

Table 149. Sinopharm Yangzhou VAC Biological Engineering Latest Developments

Table 150. Sinovet Animal Health Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 151. Sinovet Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 152. Sinovet Animal Health Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 153. Sinovet Animal Health Main Business

Table 154. Sinovet Animal Health Latest Developments

Table 155. Jofunhwa Group Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 156. Jofunhwa Group Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 157. Jofunhwa Group Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 158. Jofunhwa Group Main Business

Table 159. Jofunhwa Group Latest Developments

Table 160. Harbin Weike Biotechnology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 161. Harbin Weike Biotechnology Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 162. Harbin Weike Biotechnology Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 163. Harbin Weike Biotechnology Main Business

Table 164. Harbin Weike Biotechnology Latest Developments

Table 165. Qilu Animal Health Products Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 166. Qilu Animal Health Products Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 167. Qilu Animal Health Products Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 168. Qilu Animal Health Products Main Business

Table 169. Qilu Animal Health Products Latest Developments

Table 170. Harbin Pharmaceutical Group Bio-vaccine Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 171. Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 172. Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 173. Harbin Pharmaceutical Group Bio-vaccine Main Business

Table 174. Harbin Pharmaceutical Group Bio-vaccine Latest Developments

Table 175. Qingdao Yebio Bioengineering Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 176. Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Product Portfolios and Specifications

Table 177. Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 178. Qingdao Yebio Bioengineering Main Business

Table 179. Qingdao Yebio Bioengineering Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Pseudorabies Virus Vaccine
- Figure 2. Pseudorabies Virus Vaccine Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Pseudorabies Virus Vaccine Sales Growth Rate 2021-2032 (K Dose)
- Figure 7. Global Pseudorabies Virus Vaccine Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Pseudorabies Virus Vaccine Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2025)
- Figure 10. Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Live Attenuated Vaccine
- Figure 12. Product Picture of Inactivated Vaccine
- Figure 13. Product Picture of Others
- Figure 14. Global Pseudorabies Virus Vaccine Sales Market Share by Type in 2026
- Figure 15. Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2021-2026)
- Figure 16. Product Picture of Bartha-K61 Strain
- Figure 17. Product Picture of HB98 Strain
- Figure 18. Product Picture of C Strain
- Figure 19. Product Picture of Other
- Figure 20. Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform in 2026
- Figure 21. Global Pseudorabies Virus Vaccine Revenue Market Share by Strain Platform (2021-2026)
- Figure 22. Product Picture of Small Pack (Below 20 Doses per Vial)
- Figure 23. Product Picture of Medium Pack (20?50 Doses per Vial)
- Figure 24. Product Picture of Large Pack (Above 50 Doses per Vial)
- Figure 25. Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size in 2026
- Figure 26. Global Pseudorabies Virus Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
- Figure 27. Pseudorabies Virus Vaccine Consumed in Large-scale Swine Farming

Groups

Figure 28. Global Pseudorabies Virus Vaccine Market: Large-scale Swine Farming Groups (2021-2026) & (K Dose)

Figure 29. Pseudorabies Virus Vaccine Consumed in Breeding Farms

Figure 30. Global Pseudorabies Virus Vaccine Market: Breeding Farms (2021-2026) & (K Dose)

Figure 31. Pseudorabies Virus Vaccine Consumed in Animal Disease Control Institutions

Figure 32. Global Pseudorabies Virus Vaccine Market: Animal Disease Control Institutions (2021-2026) & (K Dose)

Figure 33. Pseudorabies Virus Vaccine Consumed in Others

Figure 34. Global Pseudorabies Virus Vaccine Market: Others (2021-2026) & (K Dose)

Figure 35. Global Pseudorabies Virus Vaccine Sale Market Share by Application (2025)

Figure 36. Global Pseudorabies Virus Vaccine Revenue Market Share by Application in 2025

Figure 37. Pseudorabies Virus Vaccine Sales by Company in 2025 (K Dose)

Figure 38. Global Pseudorabies Virus Vaccine Sales Market Share by Company in 2025

Figure 39. Pseudorabies Virus Vaccine Revenue by Company in 2025 (\$ millions)

Figure 40. Global Pseudorabies Virus Vaccine Revenue Market Share by Company in 2025

Figure 41. Global Pseudorabies Virus Vaccine Sales Market Share by Geographic Region (2021-2026)

Figure 42. Global Pseudorabies Virus Vaccine Revenue Market Share by Geographic Region in 2025

Figure 43. Americas Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)

Figure 44. Americas Pseudorabies Virus Vaccine Revenue 2021-2026 (\$ millions)

Figure 45. APAC Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)

Figure 46. APAC Pseudorabies Virus Vaccine Revenue 2021-2026 (\$ millions)

Figure 47. Europe Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)

Figure 48. Europe Pseudorabies Virus Vaccine Revenue 2021-2026 (\$ millions)

Figure 49. Middle East & Africa Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)

Figure 50. Middle East & Africa Pseudorabies Virus Vaccine Revenue 2021-2026 (\$ millions)

Figure 51. Americas Pseudorabies Virus Vaccine Sales Market Share by Country in 2025

Figure 52. Americas Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)

Figure 53. Americas Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)

Figure 54. Americas Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)

Figure 55. United States Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 56. Canada Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 57. Mexico Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 58. Brazil Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 59. APAC Pseudorabies Virus Vaccine Sales Market Share by Region in 2025

Figure 60. APAC Pseudorabies Virus Vaccine Revenue Market Share by Region (2021-2026)

Figure 61. APAC Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)

Figure 62. APAC Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)

Figure 63. China Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 64. Japan Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 65. South Korea Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 66. Southeast Asia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 67. India Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 68. Australia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 69. China Taiwan Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 70. Europe Pseudorabies Virus Vaccine Sales Market Share by Country in 2025

Figure 71. Europe Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)

Figure 72. Europe Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)

Figure 73. Europe Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)

Figure 74. Germany Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 75. France Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 76. UK Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 77. Italy Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 78. Russia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 79. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by

Country (2021-2026)

Figure 80. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)

Figure 81. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)

Figure 82. Egypt Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 83. South Africa Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 84. Israel Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 85. Turkey Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 86. GCC Countries Pseudorabies Virus Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 87. Manufacturing Cost Structure Analysis of Pseudorabies Virus Vaccine in 2026

Figure 88. Manufacturing Process Analysis of Pseudorabies Virus Vaccine

Figure 89. Industry Chain Structure of Pseudorabies Virus Vaccine

Figure 90. Channels of Distribution

Figure 91. Global Pseudorabies Virus Vaccine Sales Market Forecast by Region (2027-2032)

Figure 92. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Region (2027-2032)

Figure 93. Global Pseudorabies Virus Vaccine Sales Market Share Forecast by Type (2027-2032)

Figure 94. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Type (2027-2032)

Figure 95. Global Pseudorabies Virus Vaccine Sales Market Share Forecast by Application (2027-2032)

Figure 96. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Pseudorabies Virus Vaccine Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G52BB070F231EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G52BB070F231EN.html>